Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Eligible age
18–80 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
You may qualify if…
- ✓ 1\. Patients with advanced cancer; 2. Life expectancy \>12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
- ✓ \-
You may not qualify if…
- ✕ 1. Had accepted gene therapy before;
- ✕ 2. Severe virus infection such as HBV, HCV, HIV, et al;
- ✕ 3. Known HIV positivity;
- ✕ 4. Active infectious disease related to bacteria, virus,fungi,et al;
- ✕ 5. Other severe diseases that the investigators consider not appropriate;
- ✕ 6. Pregnant or lactating women;
- ✕ 7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
- ✕ 8. Other conditions that the investigators consider not appropriate.
Source: ClinicalTrials.gov · NCT06477614 · last updated 2024-06-27